**Appendix S2. Costs input into the model**

|  |  |  |
| --- | --- | --- |
| **Cost data**  | **Base-case values (ranges used in sensitivity analysis)****Per unit costs ($) in Australian dollars** | **References** |
| **Dialysis** |  |  |
| Annual HD – hospitalInitial accessAnnual HD – homeInitial accessAnnual HD – satelliteInitial accessAnnual CAPDAnnual APD*Proportion of dialysis modality (Australia)*Hospital HDSatellite HDHome HDCAPDAPD*Proportion of dialysis mortality* (New Zealand)Hospital HDSatellite HDHome HDCAPDAPD | $85,987 ($76,584 - $95,004)$10,896 ($9,050 - $13,578)$50,045 ($48,670 - $55,789)$9,990 ($7,561 - $12,758)$52,650 ($46,735 - $65,896)$9,990 ($8,321 - $14,890)$60,838 ($54,434 - $78,901)$86,905 ($80,010 - $90,908)23%46%9%10%12%30%19%16%24%11% | [1,2,8-12] |
| **Transplantation ( Initial – year 1)***Costs of standard immunosuppression*Tac + Prednisone + MMFCyA + Prednisone + MMFSirolimus + Prednisone + MMFEverolimus + Prednisone + MMF*Proportion of immunosupppressive therapy used*Tac + Prednisone + MMFCyA + Prednisone + MMFSirolimus + Prednisone +MMFEverolimus + Prednisone +MMF*Costs of induction therapies*BasiliximabAnti-thymoglobulin antibodies*Costs of surgery – deceased donor + harvest* *Costs of outpatient visits – (total = 32 per year)* | $25,919 ($21,436 - $28,890)$14,612 ($11,536 - $16,790)$17,218 ($15,090 - $22,643)$17,955 ($15,431 - $21,674)0.250.500.130.12$6,300 ($3,034 - $12,342)$13,175 ($5,390 - $26,678)$29,879 $2,137 ($1,890 - $26,780) | [1,2,8-12] |
| **Total costs of uncomplicated transplant** | **$49,290** | [1,2,8-12] |
| **Costs of complicated transplant** |  |  |
| **Above plus:** |  |  |
| Anti-thymoglobulin antibodies  | $13,175 |  |
| Intermittent dialysis  | $6,500 |  |
| Biopsies | $500 |  |
| **Total costs of complicated transplant** | **$69,447** | [1,2,8-12] |
| **Transplantation (Subsequent years)**Costs of standard immunosuppressionTac + Prednisone + MMFCyA + Prednisone + MMFSirolimus + Prednisone + MMFEverolimus + Prednisone + MMFProportion of immunosupppressive therapy usedTac + Prednisone + MMFCyA + Prednisone + MMFSirolimus + Prednisone + MMFEverolimus + Prednisone + MMFCosts of outpatient visits (x4 per year) | $25,919$14,612$17,218$17,9550.250.500.130.12$268 | [1,2,8-12] |
| **Total costs of subsequent transplants** | $18,446 |  |
| **Graft loss and return to dialysis** | $17,663 (8,831 - $35,326) | [8,9,11,12] |
| **Steroid responsive acute rejection** | $6,030 (3,489 – 12,114) | [8,9,11,12] |
| **Steroid-resistant acute rejection** | $43,330 ($12,904 - $43,244) | [8,9,11,12] |
| **Costs of dying from non-CVD causes** | $18,482 ($17,654 - $38,907) | [1,8,9,11-13] |
| **Cost of dying from CVD causes** | $28,228 ($23,890 - $35,435) | [1,8,9,11-13] |
| **Costs of non-fatal CVD** | $10,626 ($9,675 - $13,786) | [1,8,9,11-13] |
| **Annual maintenance costs for individuals with co-morbidities** |  |  |
|  | **Diabetes mellitus** |  |  |
|  | Endocrinology review (4 visits per year) | 298.9 | [9] |
|  | Ophthalmology review (2 visits per year) | 149.4 | [9] |
|  | Laser photocoagulation therapy (2 visits per year ) | 1500 | [9] |
|  | Podiatry review (4 visits per year) | 244.4 | [9] |
|  | Dietician review (3 visits per year) | 183.3 | [9] |
|  | Annual average costs for other concomitant medications: (anti-hypertensives (15%), statins (15%), oral hypoglycaemics (40%), insulin (30%)) | 1501.6 | [8] |
|  | **Total costs** | 2827 |  |
|  | **Cardiovascular disease**  |  |  |
|  | Cardiology review (4 visits per year) | 298.9 | [9] |
|  | Echocardiogram | 115.3 | [9] |
|  | ECG | 50.1 | [9] |
|  | Annual average costs for other concomitant medications( | 1875.6 |  |
|  | (anti-hypertensives: beta blockers, nitrates, calcium channel blockers (50%), statins (30%), anti-platelet agents (20%)) Cerebrovascular disease 1789.3 (8) |  |  |
|  | **Total costs** | 2339.9 |  |
|  | **Cerebrovascular disease**  |  |  |
|  | Neurology review ( 4 visits per year)  | 298.9 | [9] |
|  | Annual average costs for other concomitant medications(anti-hypertensives (40%), statins (30%), anti-platelet agents (30%))**Total costs** | 1825.62124.5 | [8] |
|  | **Obesity** |  |  |
|  | Dietician review (3 visits per year)  | 183.3 | [9] |
|  | Exercise physiotherapist review ( 3 visits per year) | 183.3 | [9] |
|  | Annual average costs for other concomitant medications(anti-hypertensives (50%), statins (50%), ) | 1251 | [8] |
|  | **Total costs** | 1617 |  |

Reference List

 1. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), Special data request (2009). 2005.
Ref Type: Report

 2. Australian and New Zealand Dialysis and Transplant Registry. The 30th Annual Report. 1-2-2007.

 3. Australia and New Zealand Organ Donation Registry. ANZOD Registry Report 2008. 2010. Adelaide, South Australia, 5011.

 4. Elli A, Traversi L, Ponticelli C (2000): Cardiovascular risk factors in renal transplant recipients. *International Journal of Artificial Organs* 23: 730-735.

 5. Gill JS, Abichandani R, Kausz AT, Pereira BJ (2002): Mortality after kidney transplant failure: the impact of non-immunologic factors. *Kidney International* 62: 1875-1883.

 6. Gill JS, Tonelli M, Johnson N, Kiberd B, Landsberg D, Pereira BJ (2005): The impact of waiting time and comorbid conditions on the survival benefit of kidney transplantation. *Kidney International* 68: 2345-2351.

 7. Commonwealth Department of Health and Ageing. Guidelines for the pharcaceutical industry on the preparation of submissions to the Pharmaceutical Benefits Advisory Committee. 2006. Canberra, ACT: Commonwealth Department of Health and Ageing.

 8. Australian Government Department of Health and Ageing: *Scedule of Pharmaceutical Benefits*. 10 A.D.

 9. Australian Government Department of Health and Ageing. Medicare Benefits Schedule Book. 6-11-2006.

 10. Australian Government of Health and Aging (AIHW). Australia's health 2006. 2006.

 11. Australian Government Australia Institute of Health and Welfare. AR-DRG data cubes from 2006-2007. 2007.

 12. Australian Institute of Health and Welfare. Australian Hospital Statistics ( 2003 - 2004). 2004.

 13. Hogan C, Lunney J, Gabel J, Lynn J (2001): Medicare beneficiaries' costs of care in the last year of life. *Health Affairs* 20: 188-195.